MicroRNA-34 (miR-34) is a master regulator of tumor suppression. It is downregulated in numerous cancers and inhibits malignant growth by repressing genes involved in various oncogenic signaling pathways. Consequently, miR-34 antagonizes processes that are targeted for basic cancer cell viability as well as cancer stemness, metastasis, and chemo-resistance. This broad anti-oncogenic activity holds the prospect of creating a new remedy that is effective against tumor heterogeneity. This review focuses on the molecular mechanisms of miR-34-mediated tumor suppression, pharmacologies in animal models of cancer, and a status update of a miR-34 therapy that may be among the first miRNA mimics to reach the clinic.

Keywords: miR-34, miR-34a, miRNA, miRNA replacement, miRNA therapeutics

INTRODUCTION

Results generated in recent years from genomic and proteomic approaches have changed our view on cancer. From a disease previously assumed to be manifested in the alteration of merely several genes, cancer is in fact genetically very complex. Tumor cells frequently harbor an array of mutated genes, and each tumor mass can comprise hundreds of cancer cells with distinct cancer genotypes (Jones et al., 2008; Parsons et al., 2008). As a result, approaches to cancer therapies are shifting to accommodate these new findings and to devise more effective and safer remedies. Conventional therapies, still the prevailing form of therapy, are frequently deemed too toxic or inadequate due to chemoresistance. These treatments are followed or replaced by targeted therapies that intercept pathways downstream. As a result, a cellular proto-oncogene can escape miRNA-mediated repression and, thereby, acquire a gain of function that is independent of mutations to the proto-oncogene itself (Johnson et al., 2005). A modest number of miRNAs shows a loss of function in a very broad range of cancer types, indicating that they play a central role in the regulation of tumor suppression. Among these are let-7, miR-34, and miR-200, all of which are evolutionarily conserved from plant to man and presumably control basic programs during cellular proliferation and differentiation. Correcting these deficiencies by miRNA replacement results in an activation of anti-proliferative and pro-apoptotic pathways, and cancer cell death (Bader et al., 2010; Wiggins et al., 2010). An obvious patient eligible for miRNA replacement would be one with miRNA levels that are lower in the tumor than the normal tissue. However, there is increasing evidence demonstrating that cancer cells with normal miRNA expression levels are also susceptible to miRNA treatment (Wiggins et al., 2010). A plausible explanation for this observation is the threshold phenomenon – it is likely that oncogenic pathways induced by mutations in other genes are controlled, albeit insufficiently counteracted, by the endogenous miRNA. Increasing the expression of the miRNA may enhance its antagonizing function beyond the threshold at which it becomes dominantly tumor suppressive.

MASTER TUMOR SUPPRESSOR miR-34

One of the challenges that drug developers are faced with is picking the right target. This also applies to miRNAs. There are many miRNAs that are deregulated in cancerous tissues; however, only a few of these induce robust phenotypes in cancer cells, and even fewer are potent enough to be used as therapeutics. Thus, similar to other cancer genes, it is possible that miRNAs play distinct roles in which only a subset function as ‘drivers’ of cancer progression. In addition, several other miRNAs have been associated with both
MOLECULAR MECHANISMS OF miR-34

TUMOR SUPPRESSION

How does miR-34a work? The study of miR-34a-induced phenotypes is beginning to outline a picture in which miR-34a acts as a master of tumor suppression (Figure 1). miR-34a can antagonize many different oncogenic processes by regulating genes that function in various cellular pathways (Table 1). A majority of these genes encode well-known proto-oncoproteins that represent attractive drug targets themselves. It is possible that the repression of only a few select targets is responsible for the miR-34a phenotype. Indeed, some of the miR-34a-regulated transcripts have directly been implicated during miR-34a-dependent tumor suppression (Craig et al., 2011). However, none were able to fully recapitulate the miR-34a phenotype, suggesting that the miR-34a function depends on multiple and perhaps the majority of all targets. The miR-34a-induced change on any of the targeted gene products is moderate and less than 1.23-fold for most proteins (Kaller et al., 2011). And yet, the collective repression of a wide range of target genes is likely to have a significant impact on cellular phenotypes (Selbach et al., 2008). Interestingly, miR-34a targets downregulated on the protein level were also affected on the mRNA level which suggests that miR-34a simultaneously affects protein synthesis and mRNA abundance (Kaller et al., 2011).

A major function attributed to miR-34a is the control of cellular proliferation, cell cycle, and senescence. In cancer cells, ectopic expression of miR-34a decreases cell doubling rates (Lodygin et al., 2008; Wiggins et al., 2010), leads to G1/S arrest (He et al., 2007; Lodygin et al., 2008), and transforms cells into large, flat bodies that stain positive for senescence-associated beta-galactosidase (He et al., 2007; Tsazawa et al., 2007; Lodygin et al., 2008). miR-34a is upregulated during various forms of senescence, including quiescence, replicative senescence, H2O2-induced premature senescence, and senescence induced by an oncogene (Christoffersen et al., 2009; Marx et al., 2009). In agreement with these phenotypes are transcriptome and protome profiles generated in miR-34a overexpressing cells. These results show that genes differentially expressed function predominantly in the regulation of the cell cycle (Bommer et al., 2007; Chang et al., 2007; He et al., 2007). Genes that are downregulated are enriched for those containing putative miR-34a binding sites, indicating that...
Table 1 | Gene products directly repressed by miR-34a.

| Cellular process               | Gene                        | Title                                      | Reference     |
|--------------------------------|-----------------------------|--------------------------------------------|---------------|
| Cell cycle                     | CDK4                        | Cyclin-dependent kinase 4                  | (He et al., 2007) |
|                                | CCNE2                       | Cyclin E2                                  | (He et al., 2007) |
|                                | CCND1                       | Cyclin D1                                  | (Sun et al., 2008) |
|                                | CDK6                        | Cyclin-dependent kinase 6                  | (Sun et al., 2008) |
| Apoptosis/p53 pathway          | BCL2                        | B-cell leukemia/lymphoma 2                 | (Bommer et al., 2007; Cole et al., 2009) |
|                                | SIRT1                       | Sirtuin 1, silent information regulator 1   | (Kimakuchi et al., 2008) |
|                                | YY1                         | Ying yang 1 transcription factor           | (Chen et al., 2010; Keller et al., 2011) |
|                                | BRCA5                       | Survivin                                   | (Shen et al., 2012) |
| Wnt signaling/metastasis       | JAG1                        | Jagged 1                                   | (Hashimi et al., 2009) |
|                                | WNT1                        | Wingless-related MMTV integration site member 1 | (Hashimi et al., 2009; Kim et al., 2011) |
|                                | NOTCH1                      | Notch homolog 1, translocation-associated   | (Du et al., 2012) |
|                                | LEF1                        | Lymphoid enhancer binding factor 1         | (Keller et al., 2011; Kim et al., 2011) |
|                                | WNT3                        | Wingless-type MMTV integration site member 3 | (Kim et al., 2011) |
|                                | CTNNB1                      | Beta-catenin                                | (Kim et al., 2011) |
|                                | LRP6                        | Low-density lipoprotein receptor-related protein 6 | (Kim et al., 2011) |
|                                | MTA2                        | Metastasis associated 1 family member 2    | (Keller et al., 2011) |
|                                | TP53D2                      | Tumor protein D52                          | (Keller et al., 2011) |
|                                | AXL                         | AXL receptor tyrosine kinase               | (Keller et al., 2011; Mudduluru et al., 2011) |
| Cancer cell stemness           | MYCN                        | v-myc myelocytomatosis viral related oncogene N | (Cole et al., 2008; Vais et al., 2008) |
|                                | CD44                        | Heparan sulfate proteoglycan               | (Liu et al., 2011) |
|                                | NANOG                       | NANOG homeobox transcription factor        | (Choi et al., 2011) |
|                                | SOX2                        | SOX-2 (sex determining region Y-box 2) transfection factor | (Choi et al., 2011) |
| Mitotic signaling              | MET                         | Met proto-oncogene (hepatocyte growth factor receptor) | (He et al., 2007) |
|                                | MAP2K1                      | Mitogen-activated protein kinase 1 (MEK1)  | (Ichimura et al., 2010) |
|                                | RRA1                        | Related Ras viral (ras) oncogene homolog    | (Keller et al., 2011) |
|                                | PDGFRA                      | Platelet-derived growth factor receptor, alpha | (Eiber et al., 2012) |
| Oncogenic Transcription        | E2F3                        | E2F transcription factor 3                 | (Vrech et al., 2007) |
|                                | MYB                         | v-myc myelocytomatosis viral oncogene homolog | (Kawano et al., 2008) |
|                                | MYC                         | v-myc myelocytomatosis viral oncogene homolog | (Christoffersen et al., 2008) |
| Metabolism                     | ACSL1                       | Acyl-CoA synthetase long-chain family member 1 | (Li et al., 2011) |
|                                | LDHA                        | Lactate dehydrogenase A                    | (Keller et al., 2011) |
|                                | IMPDH                       | IMP (inosine 5′-monophosphate) dehydrogenase | (Kim et al., 2012) |

Several interactions are direct. Transcripts for which the interactions with miR-34a have experimentally been validated include cyclins D1 and E2, as well as cyclin-dependent kinases 4 and 6. In addition, miR-34a directly represses a series of signaling molecules that drive cellular proliferation and roles in the mitogen-activated protein kinase (MAPK) and phosphoinositide 3-kinase (PI3K) pathways. These are mitogen-activated protein kinase kinase kinase 1 (MEKK1), MAP2K1, R-Ras (RRAS), platelet-derived growth factor receptor (PDGFRA), and hepatocyte growth factor receptor (MET).

The functions of miR-34a in the control of the cell cycle are complemented by those that regulate apoptosis. All miR-34a family members are transcriptionally induced by p53 and are important effector molecules in the execution of molecular programs directed by p53 (Bommer et al., 2007; Chang et al., 2007; He et al., 2007; Raver-Shapira et al., 2007; Tarassov et al., 2007). miR-34a represses BCL2 and survivin; however, it is possible that other mechanisms contribute to the pro-apoptotic functions of miR-34a (Bommer et al., 2007; Shen et al., 2012). Indeed, miR-34a can stimulate endogenous p53 activity in a positive feedback-loop by targeting SIRT1 (silent information regulator 1), a NAD-dependent deacetylase that deactivates TP53 (tumor protein 53), and YY1 (yin yang 1), a protein that binds to p53 and promotes p53 ubiquitination and degradation (Sui et al., 2004; Yamakuchi et al., 2008; Chen et al., 2010). Thus, it appears that miR-34a takes advantage of upstream signaling to maintain its...
own expression levels and to activate tumor suppressor pathways exclusively regulated by p53. However, the requirement for p53 in miR-34a-induced tumor suppression remains unknown. Emerging evidence suggests that endogenous p53 is not a prerequisite for miR-34a tumor suppression – miR-34a transcription can occur independently of p53, and miR-34a is capable of inhibiting cancer cells that lack endogenous p53 (Christoffersen et al., 2009; Wiggins et al., 2010).

A valuable aspect of miR-34a is its ability to inhibit cancer stem cells. Cancer stem cells, also known as tumor-initiating cells, are defined as a small fraction of cancer cells that have the ability to self-renew and to give rise to identical daughter cells (Reya et al., 2001). As such, cancer stem cells act as the “seed” of the tumor that has an enhanced propensity to form tumors in the animal, metastasize and withstand conventional cancer therapy. Thus, chemoresistance and recurrence are likely due to the presence of these tumor-initiating cells that ought to be eliminated for successful patient outcome. For instance, miR-34a levels are lower in prostate cancer stem cells that express either the CD44 or the CD133 epitope, and in those enriched in the side population when compared to the bulk of prostate tumor cells (Li et al., 2011). Overexpression of miR-34a, either by transient transfection or stable genomic integration via a retrovirus, interferes with sphere formation in soft agar and tumorigenicity in vivo (Li et al., 2011). Both are abilities that have specifically been associated with the presence of prostate cancer stem cells. miR-34a also inhibited the propagation properties of tumor-initiating cells derived from pancreatic carcinoma and medulloblastoma (Li et al., 2009; de Antonellis et al., 2011). Thus, the relative amounts of endogenous miR-34a proportionally decline as cells transform from normal to cancer and to cancer stem-like cells. This progression appears to be functionally linked to tumor viability and abolished by miR-34 replacement.

The notion that the modulation of miR-34a abundance has a direct impact on pluripotency is supported by observations that implicate miR-34a in somatic cell reprogramming (Cho et al., 2011). miR-34a prevents cell reprogramming by directly inhibiting pluripotency genes, including NANOG, SOX2, and MYCN (Cho et al., 2011). Similarly, the ability to inhibit prostate cancer stem cells was causally linked to miR-34a-dependent repression of CD44 which may further define its specific effects on cancer stem cells (Liu et al., 2011). Hence, the repression of these pluripotency genes provides a molecular explanation for miR-34a functions that govern stemness and differentiation.

Other functions ascribed to miR-34a are during inhibition of metastasis and chemoresistance. Both may be a consequence of miR-34a-induced cancer stem cell elimination but may also be an independent result of miR-34a regulation in non-stem cancer cells. The Wnt signaling pathway is intimately involved in the transition from an epithelial to a mesenchymal state (EMT) and metastasis. It is subject to miR-34a-dependent regulation at multiple levels. miR-34a and miR-34b/c directly repress the translation of WNT1 and WNT3, as well as LRPP6, a co-receptor of Frizzled that binds to Wnt ligands (Kim et al., 2011). The miR-34 family members also repress LEF1 and beta-catenin (CTNNB1) that function as the primary transcriptional mediators downstream of Wnt. Accordingly, miR-34 interferes with phenotypes attributed to Wnt signaling such as a block of Wnt-induced axis duplication during Xenopus development, a decrease in the tissue-invasive activity of colorectal cancer cells and inhibition of TCF/LEF target genes (Kim et al., 2011). Interestingly, several of the genes transcriptionally induced by TCF/LEF are CCND1, MYC, and CD44 that are also independently repressed by miR-34a. The miRNA also downregulates other pro-metastatic genes not necessarily linked to the Wnt signaling pathway (MET, AXL, MTA2; He et al., 2007; Keller et al., 2011). This corroborates the concept that the regulatory mechanisms of miRNAs involve multiple components within a given pathway and across several others.

The ability to impact multiple cellular pathways may also suggest that miR-34a can act synergistically with conventional, cytotoxic therapies. The modes of action of both drug classes are likely sufficiently distinct for the combination to provide an added benefit. This has experimentally been tested in cancer cell models of prostate, pancreas, colon, bladder, stomach, and brain. As shown in Table 2, miR-34a mitigates resistance to taxol and platinum-based agents, as well as resistance to a few others. The effects of the combination in normal tissues are currently unknown. The mechanisms through which miR-34a exerts its chemo-sensitizing functions remain ill-defined and require further study; and yet, the preliminary data derived from these cell models may indicate that the utility of a future miR-34a therapeutic can be substantially expanded.

**PHARMACOLOGY OF miR-34 IN ANIMAL MODELS OF CANCER**

The biological activity of miR-34a identified in cell models suggests that it can also suppress tumor growth in vivo. Although a thorough assessment of miR-34a activity in animals primarily hinges on the performance of in vivo delivery systems, there are a few examples that illustrate its therapeutic potential (Table 3). A common approach to achieve miRNA expression in vivo is based on vectoral systems that function similarly to those used for traditional gene therapy (Esquela-Kerscher et al., 2008; Kumar et al., 2008; Kota et al., 2009; Qiu et al., 2011). These can be used either on xenografts before transplantation or systemically as nanoparticles by parenteral administration. Another approach is in form of nanoparticles that contain ~19–23-nt double-stranded miRNA mimics and can be administered by intravenous tail vein injections (Chen et al., 2010; Wiggins et al., 2010). Here, examples of the systemic delivery mode are discussed in further detail.

One example of systemic delivery is provided by the intravenous delivery of miR-34a in polyacytic liposome-hyaluronic acid nanoparticles that are modified with a GCA single-chain antibody fragment (scFv; Chen et al., 2010). The antibody moiety facilitates tumor targeting to human glioma tumor sphere cells as well as murine B16 melanoma cells. To test the therapeutic utility, the formulation was administered on two consecutive days (0.5 mg/kg) to mice that had lung metastases induced by the B16F10 melanoma xenograft. Eleven days after the first treatment, the tumor burden was reduced by approximately 50% as assessed by luminescence imaging of metastatic lesions. In a separate experiment, miR-34a activity was confirmed by an increase of...
Table 2 | Effects of miR-34a in combination with conventional therapies.

| Cancer therapy | Cancer type | Effects of the miR-34a/chemo combination | Reference |
|----------------|-------------|------------------------------------------|-----------|
| Camptothecin   | Prostate    | Reduced cell viability                   | (Fujita et al., 2008) |
| Paclitaxel     | Prostate    | Attenuates chemoresistance                | (Kojima et al., 2010) |
| 5-Fluorouracil | Colon       | Attenuates chemoresistance                | (Kuo et al., 2010)   |
| Mitomycin C    | Brain       | ~2-fold lower IC50 than chemo alone      | (Weeraratne et al., 2010) |
| Cisplatin      | Bladder     | Reduced clonogenic potential, increased senescence | (Small et al., 2011) |
|                | Pancreas    | 2.7-fold lower IC50 than chemo alone     | (Li et al., 2009)    |
| Mitomycin C    | Brain       | ~2-fold lower IC50 than chemo alone      | (Weeraratne et al., 2010) |
| Cisplatin      | Stomach⁺    | 1.8-fold lower IC50 than chemo alone     | (Ji et al., 2008)    |
| Docetaxel      | Pancreas    | 3.2-fold lower IC50 than chemo alone     | (Ji et al., 2009)    |
| Docetaxel      | Stomach⁹    | 2.4-fold lower IC50 than chemo alone     | (Ji et al., 2008)    |
| Gemcitabine    | Pancreas    | 2.6-fold lower IC50 than chemo alone     | (Ji et al., 2009)    |
| Docetaxel      | Stomach⁹    | 2.6-fold lower IC50 than chemo alone     | (Ji et al., 2008)    |
| Doxorubicin    | Stomach⁹    | 2.0-fold lower IC50 than chemo alone     | (Ji et al., 2008)    |

*Values were generated in cancer cells with high BCL2 levels.

Table 3 | Therapeutic activity of miR-34a in animal models of cancer.

| Cancer type | Mouse tumor model | Effects (TGI)¹ | Reference |
|-------------|-------------------|----------------|-----------|
| Non-small cell lung cancer | s.c. H460 xenograft | ~78% TGI | (Wiggins et al., 2010) |
|             | s.c. A549 xenograft | ~62% TGI | (Wiggins et al., 2010) |
| Prostate cancer | o.t. PC3 xenograft | ~60% TGI | (Fan et al., 2011) |
| Melanoma | metastatic B16 xenograft | ~83% TGI | (Li et al., 2011) |
| Pancreatic cancer | s.c. MiaPaca-2 xenograft | ~62% TGI | (Pramanik et al., 2011) |
| Lymphoma | s.c. U2932 xenograft | ~76% TGI | (Craig et al., 2012) |

¹Effects are expressed as percentage TGI in miR-34a-treated animals compared to controls. TGI indicates a complete block of tumor development. TGI was determined by either caliper measurements, tumor area, tumor weight, ultra sound, or luminescence of luc-expressing tumor cells. s.c., subcutaneous; o.t., orthotopic; TGI, tumor growth inhibition.

miR-34a-induced apoptosis and the downregulation of survivin protein levels in lung metastases.

Pramanik et al. (2011) investigated the therapeutic potential of miR-34a in subcutaneous and orthotopic pancreas MiaPaca-2 xenografts. miR-34a was delivered systemically using a 100 nm-lipid-based nanoparticle that contains a miR-34a-encoding vector. Animals with confirmed tumors were treated three times a week for three consecutive weeks, and tumor growth was determined by either caliper measurements or ultra sound. The data showed that tumors from mice treated with miR-34a were significantly smaller and showed signs of necrosis and apoptosis. Orthotopic tumors also displayed reduced levels of Ki67. In addition, SIRT1 protein as well as CD44 and ALDH mRNA levels were reduced in subcutaneous tumor tissues of miR-34a-treated animals.

A series of experiments were performed with a neutral lipid emulsion (NLE) that forms particles in the nanometer range and carry a net charge close to zero. Proof of concept for the therapeutic utility of the miR-34a/NLE formulation was generated in subcutaneous H460 and A549 non-small cell lung cancer xenografts (Wiggins et al., 2010). Mice carrying palpable H460 tumors received a dose of 3 mg/kg via intravenous tail vein injections every 3 days over a period of 9 days. A549-carrying animals were dosed at 1 mg/kg every other day for a total of 15 days. In comparison to controls, tumor growth of miR-34a-treated groups was inhibited by 78 and 62%, respectively. Both xenografts displayed an increase in apoptosis and a reduction in proliferation. The anti-oncogenic effects were accompanied by an accumulation of the miR-34a mimic in tumor tissues and a downregulation of MET, CDK4, and BCL2 protein levels (Wiggins et al., 2010).
Similar results were obtained in a genetically engineered mouse model of lung cancer that is based on the constitutively active KRAS mutant G12D (Trang et al., 2011). Ten weeks after the activation of the KRAS-G12D mutant and the initiation of orthotopic lung tumors, miR-34a mimics conjugated with NLE were systemically introduced every other day for a total of eight injections at a concentration of 1 mg/kg each time. At sacrifice, mice given a NLE formulation that contained a scramble negative control oligonucleotide showed extensive diffuse hyperplasia and adenomas in lungs. In contrast, the lesions observed in miR-34a-treated animals were few and significantly smaller. The remaining tumor area was only 40% of the overall tumor area that was noted in controls. This result corresponded with a significant elevation of miR-34a levels in lung tissue, reduced expression of Ki67 and an increase in TUNEL-positive cells.

In models of prostate cancer, the efficacy of miR-34a complexed in NLE was demonstrated by Liu et al. (2011). Orthotopic PC-3 tumors were generated by the surgical implantation of tumor cells into the dorsal prostate of male NOD/SCID mice and allowed to grow for 3 weeks. Then, mice were treated every other day by intravenous tail injections using a dose of 1 mg/kg per administration. After the fifth dose, mice were sacrificed to determine tumor weights. Tumors were half the weight of those from control animals (Liu et al., 2011). A similar experimental set-up was used to evaluate miR-34a activity in the orthotopic LAPC9 tumor xenograft. In these animals, the effect on the primary tumor was only moderate (20% tumor inhibition). However, animals in the miR-34a study group greatly benefitted from significantly enhanced survival, most likely due to a substantial decrease in LAPC9 metastasis to lung and other organs (Liu et al., 2011).

During the transition from low-grade to high-grade cancers, diffuse large B-cell lymphomas frequently show a gain of MYC function and a concurrent loss of miR-34a. Reintroduction of miR-34a mimics into cultured lymphoma cells proved to be more effective in inhibiting lymphoma cells than siRNAs directed against MYC or FOXP1, another key oncogene in this type of cancer. This suggests that miR-34a replacement is the preferred therapeutic modality in this model (Craig et al., 2011).

To explore this experimentally, mice with existing subcutaneous U2932 lymphoma xenografts were given intravenous injections of tumor cells into the dorsal prostate of male NOD/SCID mice and allowed to grow for 3 weeks. Then, mice were treated every other day by intravenous tail injections using a dose of 1 mg/kg per administration. After the fifth dose, mice were sacrificed to determine tumor weights. Tumors were half the weight of those from control animals (Liu et al., 2011). A similar experimental set-up was used to evaluate miR-34a activity in the orthotopic LAPC9 tumor xenograft. In these animals, the effect on the primary tumor was only moderate (20% tumor inhibition). However, animals in the miR-34a study group greatly benefitted from significantly enhanced survival, most likely due to a substantial decrease in LAPC9 metastasis to lung and other organs (Liu et al., 2011).

The transition from bench to bedside of a miR-34a-based cancer therapy depends on the availability of a clinically relevant delivery system. Many technologies that were used to establish proof of concept in the animal are promising candidates but are not advanced far enough to demonstrate the robustness, scalability, and quality controls necessary to support clinical trials.

To accelerate the path to the clinic, Mirna Therapeutics screened multiple existing delivery systems that are in pre-clinical development or have already entered clinical testing with other oligonucleotide therapeutics. This evaluation encompassed an assessment of (i) efficacy in appropriate mouse models of cancer, (ii) miRNA biodistribution, and (iii) preliminary safety. The delivery technology with the best combination of efficacy, biodistribution, and safety was the NOV340 technology (SMARTICLES®, Marina Biotech, Bothell, WA; Mirna Therapeutics Inc., 2011), an ionizable liposome that forms a particle with a diameter of ~120 nm. The liposome contains amphoteric lipids that are cationic at low pH and neutral or anionic at neutral and higher pH. The lipids and miRNA mimics are mixed under acidic conditions to facilitate efficient miRNA encapsulation and liposome formation. In biofluids with a pH of 7–7.5, the nanoparticles assume a slightly anionic character that may prevent unwanted interactions with the negative charge of cellular membranes in the endothelium and other tissues. Since the pH tends to be lower in tumor areas, the NOV340 particles may become cationic in these areas and adhere to tumor cells.

The pharmacology of the NOV340/miR-34a formulation was tested in an orthotopic model of hepatocellular carcinoma. A model of liver cancer was chosen because (i) the majority of hepatic malignancies present mutations in pathways that can be antagonized by miR-34a (Catalogue of Somatic Mutations in Cancer),
(ii) miR-34a inhibits human hepatocellular carcinoma cells in culture (Liu et al., 2009), and (iii) efficient NOV34 liposome delivery to liver. The data showed that transfection of mice carrying existing cancers led to a significant tumor regression and prolonged survival (Daige et al., 2011; Rodie et al., 2012). A histologic examination of livers revealed that several of the mice appeared to be tumor-free. This was in stark contrast to mice dosed with NOV34 particles that were loaded with a scramble control. The NOV34/miR-34-treated animals lacked notable drug-related side effects as determined by normal organ morphology, blood chemistry, and serum cytokine levels.

In summary, the data demonstrate the therapeutic utility of the clinically relevant NOV34/miR-34 formulation in a model of hepatocellular carcinoma. Mirna Therapeutics has initiated a preclinical development program to support the manufacture of cGMP materials and the conduct of IND-enabling studies. The company anticipates initiating clinical trials in 2013 for miR-34 cGMP materials and the conduction of IND-enabling studies. The project aims to restore a loss of function that has been a largely inacces-

CLOSING REMARKS

The replacement of miRNAs provides a new therapeutic concept. It aims to restore a loss of function that has been a largely inaccessible approach for drug developers. In addition, it builds on the regulation of multiple cellular pathways associated with human disease which appears to be a requirement for successful cancer therapy. Data generated in the animal model suggests that the robust cGMP
collegial delivery of miRNA mimics effectively inhibits tumor growth and is well-tolerated by normal tissues. This has cleared the path for a miR-34 therapy to the clinic. The emphasis is now on safety in higher species and man.

ACKNOWLEDGMENTS

The author thanks Drs Annette Schlaeger, Paul Lammers, and David Brown for critical reading of the manuscript. This work was supported by a grant from the National Institutes of Health (1R43CA137939) and a commercialization grant from the Cancer Prevention and Research Institute of Texas (CPRIT).
Ichimura, A., Ruike, Y., Terasawa, Greenberg, E., Hershkovitz, L., Itzhaki, Frontiers in Genetics Bader Development of a miR-34-based cancer therapy Y., Chen, Y. H., Chen, G. H., and K562 cells. proliferation by repressing mitogen-
H., Shimizu, K., and Tsujimoto, G. non-receptor tyrosine kinase 3.0: genomic maps of microRNAs in
Huang, H. D. (2008). miRNAMap
K., Zhang, X., Parsons, D. W., and their target genes JAG1 and WNT1
Lee, B. (2009). MicroRNA profiling
Lowe, S. W., Cleary, M. A., and chemoresistance in prostate cancer
Zender, L., Magnus, J., Ridzon, D., p53 tumour suppressor network.
Keisari, Y., Besser, M. J., Schachter, R., Gefen, N., Edry, L., Modai, S.,
R., Huang, F. D., Vouk, J. I., and Weiss, S. J. (2011). p53
Liu, X., Sempere, L. F., Ouyang, H., effects of miR-34a on cell growth
D., and Slack, F. J. (2005). RAS is reg-
Jones, S., Zhang, X., Chen, Y., Lu, W., B., and branched evolution revealed by
W., Wu, Y., and Zheng, X. (2008). miR-34a downregulates Ras signaling by
M., Eklund, A. C., Spencer-Dene, C., Santos, C. R., Nohadani, S., Larkin, J., Endesfelder, D., Gron-
Development of a miR-34-based cancer therapy

Parsons, D. W., Jones, S., Zhang, X., Lin, J. C., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Siu, I. M., Gallia, G. L., Olive, A., McLendon, R., Reddish, B. A., Koss, S., Nikolikova, T., Nikolikov, Y., Baum, D. A., Terekh, H., Davis, J. A., Jr., Harrigan, J., Smith, D. R., Straubing, R. L., Marti, S. K., Shibata, S. M., Yen, H., Riggins, G. J., Bigner, D. D., Kirchen, P., Rapaport, D., Parampalli, G., Vogelstein, B., Vardaroglu, S. E., and Kiddie, R. W. (2008). An integrated genomic analysis of human glioblastoma multiforme Science 321, 1087–1122.

Franklin, D., Campbell, N. R., Karkari, C., Choudhri, K., Reit, O. A., Mendell, J. T., and Mattia, A. (2011). Restoration of tumor suppressor microRNAs using a systemic nanovector inhibits pancreatic cancer growth in mice. Mol. Cancer Ther. 10, 1470–1480.

Qiu, X., Freedman, J. M., and Liang, G. (2011). Creating a flexible multiple microRNA expression vector by linking promoter microRNAs. Biochem. Biophys. Res. Commun. 411, 279–284.

Raser-Shapira, N., Marciano, E., Meir, E., Spitzer, Y., Bosenfeld, N., Moskovits, N., Benzerdeh, Z., and Oren, M. (2007). Transcriptional activation of p53-miRNA contributors to p53-mediated apoptosis. Mol. Cell 26, 271–283.

Rezn, T., Morrison, S. J., Clarke, M. E., and Weinman, J. L. (2001). Stem cells, cancer, and cancer stem cells. Nature 414, 105–111.

Sahel, J. A., Meire, J. R., Thierfelder, N., Song, Y., Khan, R., and Rajkhowa, N. (2000). Widespread changes in protein expression induced by microRNAs. Nature 401, 50–53.

Shen, Z., Zhou, G., Yu, D., Ren, Y., Cheng, L., Wu, Z., and Guo, J. (2012). MicroRNA-34a affects the occurrence of lymphatic squamous cell carcinoma by targeting the anti-apoptotic gene survivin. Mol. Oncol. doi:10.1016/j.molonc.2012.03.010.9

Silot, J., Jacobson, A., Orovec, T., Harnath, G., Fultone, A., Sanders, C., Holland, E. C., and Hauge, J. T. (2012). miR-34a repression in prostatic malignant glandular upregulates expression of its target PDE4B and promotes tumorigenesis. PLoS ONE 7, e39844. doi:10.1371/journal.pone.0039844

Saito, M., Arakawa, K., Suzuki, T., Takeuchi, K., Shimasaki, Y., Ishida, O., Shindo, A., and Tsujimoto, Y. (2009). B-cell lymphoma-1 inactivation of miR-34a, miR-127, and miR-154 can efficiently suppress murine lymphomas. Proc. Natl. Acad. Sci. U.S.A. 106, 22052–22057.

Santos, C. E., Spector, Y., Rosenfeld, N., Trang, P., Wiggins, J. F., Daige, C. L., Tryndyak, V. P., Ross, S. A., Beland, A., Meister, G., and Hermeking, H. (2011). Frequent concomitant inactivation of miR-34a and miR-216 by CpG methylation in colorectal, pancreatic, mammary, ovarian, and renal cell carcinomas and soft tissue sarcomas. Virology Arch. 349, 315–322.

Sheng, X., Wang, X., Wang, H. K., McCoy, J. P., Banerjee, N. S., Reddy, J. S., Bucker, T. R., Meyers, C., Chen, L. T., and Zheng, J. M. (2009). Oncogenic HPV selectivity interrupts the expression of tumor-suppressive miR-34a through viral oncoprotein E7. RNA 15, 657–647.

Weinstein, S. O., Amarni, V., Nims, A., Toledi, N., Scott, D. K., Pomero, S. L., and Ouy, Y. J. (2010). miR-21 confers chemosensitivity through modulation of MAGE-A and p53 in melanoma. Nat. Med. 16, 165–173.

Wei, J. S., Song, Y. K., Durair, S., Chen, Q., Qi, R., Cheek, A. T., Tang, P., Zhang, Q., Thiere, C., Slack, A., Shektor, J., and Khram, J. (2010). The MCVN oncoogene is a direct target of miR-34a. Oncogene 29, 5241–5251.

Welch, C., Chen, Y., and Stallings, R. L. (2007). MicroRNA-34a functions as a potential tumor suppressor by inducing apoptosis in neuroblastoma cells. Oncogene 26, 5017–5022.

Welch, S. A. and Moore, J. J. (2007). Ectodermal success of a molecularly targeted agent for the treatment of advanced pancreatic cancer. Future Oncol. 3, 245–254.

Wiggins, J. E., Blikslffer, L., Koulour, K., Otmotusa, M., Patrawala, L., Brown, D., and Bader, A. G. (2010). Development of a lung cancer therapeutic based on the tumor suppressor microRNA-34A. Cancer Res. 70, 5925–5930.

Yamamichi, M., Ferlin, M., and Lowen, C. J. (2008). miR-143-MicroRNA regulation of apoptosis. Proc. Natl. Acad. Sci. U.S.A. 105, 15421–15426.

Yan, D., Zhou, X., Chen, X., Hu, D. N., Dong, X. D., Wang, L., Pe, J., Li, Q., and Qiu, J. (2009). MicroRNA-34a inhibits uveal melanoma cell proliferation and migration through down-regulation of c-Met. Invest. Ophthal. Mol. Vis. Sci. 50, 1559–1565.

Yan, K., Gao, J., Yang, T., Ma, Q., Qiu, X., Fan, Q., and Ma, B. (2012). MicroRNA-34a inhibits the proliferation and metastasis of osteosarcoma cells both in vitro and in vivo. PLoS ONE 7, e35578. doi:10.1371/journal.pone.0035578

Conflict of Interest Statement: The author is an employee of MiRa Therapeutics and declares potential conflicts of interest relevant to the subject matter or materials discussed in this article.

Received: 30 April 2012; accepted: 14 June 2012; published online: 02 July 2012.

Citation: Bader AG (2012) miR-34—a microRNA replacement therapy is headed to the clinic. Front. Genet. 3, 201–207.

This article was submitted to Frontiers in Non-Coding RNA, a specialty of Frontiers in Genetics.

Copyright © 2012 Bader. This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License, which permits non-commercial use, distribution, and reproduction in other forums, provided the original authors and source are credited.